Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Vfend

VFEND 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 48–49

48 Non-steroidal selective mineralocorticoid receptor (MR) antagonists Finerenone Although not studied, voriconazole Contraindicated (see section [CYP3A4 substrate] is likely to significantly increase 4.3) the plasma concentrations of finerenone. Eplerenone Although not studied, voriconazole Contraindicated (see section [CYP3A4 substrate] is likely to significantly increase 4.3) the plasma concentrations of eplerenone. Non-steroidal anti-inflammatory drugs (NSAIDs) [CYP2C9 substrates] Frequent monitoring for adverse S-Ibuprofen Cmax  20% reactions and toxicity related to Ibuprofen (400 mg single dose) S-Ibuprofen AUC0-  100% NSAIDs is recommended. Dose reduction of NSAIDs may be Diclofenac (50 mg single dose) Diclofenac Cmax  114% needed. Diclofenac AUC0-  78% Opioids Long-Acting Opiates In an independent published study, Dose reduction in oxycodone and [CYP3A4 substrates] Oxycodone Cmax  1.7-fold other long-acting opiates Oxycodone AUC0-  3.6-fold metabolised by CYP3A4 Oxycodone (10 mg single (e.g., hydrocodone) should be dose) considered. Frequent monitoring for opiate-associated adverse reactions may be necessary. Methadone (32-100 mg QD) R-methadone (active) Cmax  31% Frequent monitoring for adverse [CYP3A4 substrate] R-methadone (active) AUC  47% reactions and toxicity related to S-methadone Cmax  65% methadone, including QTc S-methadone AUC  103% prolongation, is recommended. Dose reduction of methadone may be needed. Short-acting Opiates Dose reduction of alfentanil, [CYP3A4 substrates] fentanyl and other short-acting opiates similar in structure to Alfentanil (20 μg/kg single In an independent published study, alfentanil and metabolised by dose, with concomitant Alfentanil AUC0-  6-fold CYP3A4 (e.g., sufentanil) should naloxone) be considered. Extended and frequent monitoring for Fentanyl (5 g/kg single dose) In an independent published study, respiratory depression and other Fentanyl AUC0-  1.34-fold opiate-associated adverse reactions is recommended. Opioid receptor antagonists Naloxegol Although not studied, voriconazole Contraindicated (see section [CYP3A4 substrate] is likely to significantly increase 4.3) the plasma concentrations of naloxegol. Oral contraceptives Oral Contraceptives* Ethinylestradiol Cmax  36% Monitoring for adverse reactions [CYP3A4 substrate; CYP2C19 Ethinylestradiol AUC  61% related to oral contraceptives, in inhibitor] Norethisterone Cmax  15% addition to those for Norethisterone/ethinylestradiol Norethisterone AUC  53% voriconazole, is recommended. (1 mg/0.035 mg QD) Voriconazole Cmax  14% Voriconazole AUC  46%

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) diclofenac (HOS-085903) ibuprofen (HOS-087884) methadone (HOS-086198) eplerenone (HOS-089050) oxycodone (HOS-109487) finerenone (HOS-109430) naloxegol (HOS-109428) hydrocodone (HOS-109488) naloxone (HOS-109490) fentanyl (HOS-086196) sufentanil (HOS-109489)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage e6233d476ccce7daca52d1dd2aaaa91e8c3161bd371e92e18ca8a2257625f3c2 · Zeichen 27978–32284 im Abschnitt

Wechselwirkungen · Vfend

VFEND 40 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 80–81

HOS-109619 · Präparat HOS-093201

80 Non-steroidal selective mineralocorticoid receptor (MR) antagonists Finerenone Although not studied, voriconazole Contraindicated (see section [CYP3A4 substrate] is likely to significantly increase 4.3) the plasma concentrations of finerenone. Eplerenone Although not studied, voriconazole Contraindicated (see section [CYP3A4 substrate] is likely to significantly increase 4.3) the plasma concentrations of eplerenone. Non-steroidal anti-inflammatory drugs (NSAIDs) [CYP2C9 substrates] Frequent monitoring for adverse S-Ibuprofen Cmax  20% reactions and toxicity related to Ibuprofen (400 mg single dose) S-Ibuprofen AUC0-  100% NSAIDs is recommended. Dose reduction of NSAIDs may be Diclofenac (50 mg single dose) Diclofenac Cmax  114% needed. Diclofenac AUC0-  78% Opioids Long-Acting Opiates In an independent published study, Dose reduction in oxycodone and [CYP3A4 substrates] Oxycodone Cmax  1.7-fold other long-acting opiates Oxycodone AUC0-  3.6-fold metabolised by CYP3A4 Oxycodone (10 mg single (e.g., hydrocodone) should be dose) considered. Frequent monitoring for opiate-associated adverse reactions may be necessary. Methadone (32-100 mg QD) R-methadone (active) Cmax  31% Frequent monitoring for adverse [CYP3A4 substrate] R-methadone (active) AUC  47% reactions and toxicity related to S-methadone Cmax  65% methadone, including QTc S-methadone AUC  103% prolongation, is recommended. Dose reduction of methadone may be needed. Short-acting Opiates Dose reduction of alfentanil, [CYP3A4 substrates] fentanyl and other short-acting opiates similar in structure to Alfentanil (20 μg/kg single In an independent published study, alfentanil and metabolised by dose, with concomitant Alfentanil AUC0-  6-fold CYP3A4 (e.g., sufentanil) should naloxone) be considered. Extended and frequent monitoring for Fentanyl (5 g/kg single dose) In an independent published study, respiratory depression and other Fentanyl AUC0-  1.34-fold opiate-associated adverse reactions is recommended. Opioid receptor antagonists Naloxegol Although not studied, voriconazole Contraindicated (see section [CYP3A4 substrate] is likely to significantly increase 4.3) the plasma concentrations of naloxegol. Oral contraceptives Oral Contraceptives* Ethinylestradiol Cmax  36% Monitoring for adverse reactions [CYP3A4 substrate; CYP2C19 Ethinylestradiol AUC  61% related to oral contraceptives, in inhibitor] Norethisterone Cmax  15% addition to those for Norethisterone/ethinylestradiol Norethisterone AUC  53% voriconazole, is recommended. (1 mg/0.035 mg QD) Voriconazole Cmax  14% Voriconazole AUC  46%

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) diclofenac (HOS-085903) ibuprofen (HOS-087884) methadone (HOS-086198) eplerenone (HOS-089050) oxycodone (HOS-109487) finerenone (HOS-109430) naloxegol (HOS-109428) hydrocodone (HOS-109488) naloxone (HOS-109490) fentanyl (HOS-086196) sufentanil (HOS-109489)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 5c1a7a3fda98976f51693be4906d67df598ab85a4fcf5f8cd51e8c0fe387196a · Zeichen 27504–31810 im Abschnitt

Wechselwirkungen · Pegasys

Pegasys 90 micrograms solution for injection in pre-filled syringe Pegasys 135 micrograms solution for injection in pre-filled syringe Pegasys 180 micrograms solution for injection in pre-filled syringe · Abschnitt 4.5 · PDF-Seite 16

HOS-109805 · Präparat HOS-093265

In a pharmacokinetic study of 24 HCV patients concomitantly receiving methadone maintenance therapy (median dose 95 mg; range 30 mg to 150 mg), treatment with Pegasys 180 micrograms sc once weekly for 4 weeks was associated with mean methadone levels that were 10% to 15% higher than at baseline. The clinical significance of this finding is unknown; nonetheless, patients should be monitored for the signs and symptoms of methadone toxicity. Especially in patients on a high dose of methadone, the risk for QTc prolongation should be considered.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-09-22T12:00:00Z · SHA-256 d1a2dc533bd5ba4d4a21ad6973e4498c4ffde781c784ae67bbeeda36922e6382 · Passage 0c07c759e8bfd82061cd6053f6c0bb6ca29554e10b2f45bdb3628cb25beed311 · Zeichen 911–1457 im Abschnitt

Wechselwirkungen · Pegasys

Pegasys 180 micrograms solution for injection · Abschnitt 4.5 · PDF-Seite 54

HOS-109868 · Präparat HOS-093265

In a pharmacokinetic study of 24 HCV patients concomitantly receiving methadone maintenance therapy (median dose 95 mg; range 30 mg to 150 mg), treatment with Pegasys 180 micrograms sc once weekly for 4 weeks was associated with mean methadone levels that were 10% to 15% higher than at baseline. The clinical significance of this finding is unknown; nonetheless, patients should be

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-09-22T12:00:00Z · SHA-256 d1a2dc533bd5ba4d4a21ad6973e4498c4ffde781c784ae67bbeeda36922e6382 · Passage 728d02d6dc36159d534b02576e0639cabf07800f13bacbab8657a372eeecfd6c · Zeichen 911–1293 im Abschnitt

Wechselwirkungen · Pegasys

Pegasys 180 micrograms solution for injection · Abschnitt 4.5 · PDF-Seite 54–55

HOS-109869 · Präparat HOS-093265

54 monitored for the signs and symptoms of methadone toxicity. Especially in patients on a high dose of methadone, the risk for QTc prolongation should be considered.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-09-22T12:00:00Z · SHA-256 d1a2dc533bd5ba4d4a21ad6973e4498c4ffde781c784ae67bbeeda36922e6382 · Passage 35d9863f89a59b19d6f15752ef20644c6983266b34d6361a30920020e0532365 · Zeichen 1347–1514 im Abschnitt

Wechselwirkungen · Viread

Viread 123 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 20

HOS-110543 · Präparat HOS-093385

Studies conducted with other medicinal products There were no clinically significant pharmacokinetic interactions when tenofovir disoproxil was co-administered with emtricitabine, lamivudine, indinavir, efavirenz, nelfinavir, saquinavir (ritonavir boosted), methadone, ribavirin, rifampicin, tacrolimus, or the hormonal contraceptive norgestimate/ethinyl oestradiol.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) norgestimate (HOS-110544) nelfinavir (HOS-084520) methadone (HOS-086198) lamivudine (HOS-085829) ribavirin (HOS-088127) saquinavir (HOS-084522) tacrolimus (HOS-085202) efavirenz (HOS-087947) ritonavir (HOS-084521) emtricitabine (HOS-085840)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 83399d7c05202dd19f8869e7fff1b0b79c80c11ccfc6a80aadea42bad4cc1d9c · Zeichen 35885–36251 im Abschnitt

Wechselwirkungen · Viread

Viread 163 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 60

HOS-110635 · Präparat HOS-093385

Studies conducted with other medicinal products There were no clinically significant pharmacokinetic interactions when tenofovir disoproxil was co-administered with emtricitabine, lamivudine, indinavir, efavirenz, nelfinavir, saquinavir (ritonavir boosted), methadone, ribavirin, rifampicin, tacrolimus, or the hormonal contraceptive norgestimate/ethinyl oestradiol.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) norgestimate (HOS-110544) nelfinavir (HOS-084520) methadone (HOS-086198) lamivudine (HOS-085829) ribavirin (HOS-088127) saquinavir (HOS-084522) tacrolimus (HOS-085202) efavirenz (HOS-087947) ritonavir (HOS-084521) emtricitabine (HOS-085840)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 83399d7c05202dd19f8869e7fff1b0b79c80c11ccfc6a80aadea42bad4cc1d9c · Zeichen 39159–39525 im Abschnitt

Wechselwirkungen · Viread

Viread 204 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 100

HOS-110725 · Präparat HOS-093385

Studies conducted with other medicinal products There were no clinically significant pharmacokinetic interactions when tenofovir disoproxil was co-administered with emtricitabine, lamivudine, indinavir, efavirenz, nelfinavir, saquinavir (ritonavir boosted), methadone, ribavirin, rifampicin, tacrolimus, or the hormonal contraceptive norgestimate/ethinyl oestradiol.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) norgestimate (HOS-110544) nelfinavir (HOS-084520) methadone (HOS-086198) lamivudine (HOS-085829) ribavirin (HOS-088127) saquinavir (HOS-084522) tacrolimus (HOS-085202) efavirenz (HOS-087947) ritonavir (HOS-084521) emtricitabine (HOS-085840)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 83399d7c05202dd19f8869e7fff1b0b79c80c11ccfc6a80aadea42bad4cc1d9c · Zeichen 39159–39525 im Abschnitt

Wechselwirkungen · Viread

Viread 245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 142

HOS-110816 · Präparat HOS-093385

Studies conducted with other medicinal products There were no clinically significant pharmacokinetic interactions when tenofovir disoproxil was co-administered with emtricitabine, lamivudine, indinavir, efavirenz, nelfinavir, saquinavir (ritonavir boosted), methadone, ribavirin, rifampicin, tacrolimus, or the hormonal contraceptive norgestimate/ethinyl oestradiol.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) norgestimate (HOS-110544) nelfinavir (HOS-084520) methadone (HOS-086198) lamivudine (HOS-085829) ribavirin (HOS-088127) saquinavir (HOS-084522) tacrolimus (HOS-085202) efavirenz (HOS-087947) ritonavir (HOS-084521) emtricitabine (HOS-085840)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 83399d7c05202dd19f8869e7fff1b0b79c80c11ccfc6a80aadea42bad4cc1d9c · Zeichen 39235–39601 im Abschnitt

Wechselwirkungen · Viread

Viread 33 mg/g granules · Abschnitt 4.5 · PDF-Seite 184

HOS-110912 · Präparat HOS-093385

Studies conducted with other medicinal products There were no clinically significant pharmacokinetic interactions when tenofovir disoproxil was co-administered with emtricitabine, lamivudine, indinavir, efavirenz, nelfinavir, saquinavir (ritonavir boosted), methadone, ribavirin, rifampicin, tacrolimus, or the hormonal contraceptive norgestimate/ethinyl oestradiol.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) norgestimate (HOS-110544) nelfinavir (HOS-084520) methadone (HOS-086198) lamivudine (HOS-085829) ribavirin (HOS-088127) saquinavir (HOS-084522) tacrolimus (HOS-085202) efavirenz (HOS-087947) ritonavir (HOS-084521) emtricitabine (HOS-085840)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 83399d7c05202dd19f8869e7fff1b0b79c80c11ccfc6a80aadea42bad4cc1d9c · Zeichen 36283–36649 im Abschnitt

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 24

HOS-112118 · Präparat HOS-093615

The mechanism of interaction is CYP3A4 and UGT1A1 inhibition. Concentrations of atazanavir (when given with ritonavir) were not significantly affected. Methadone, stable maintenance No significant effect on methadone No dosage adjustment is necessary dose concentrations was observed. Given that if methadone is co-administered (atazanavir 400 mg once daily) low dose ritonavir (100 mg twice daily) with REYATAZ. has been shown to have no significant effect on methadone concentrations, no interaction is expected if methadone is co- administered with REYATAZ, based on these data. PULMONARY ARTERIAL HYPERTENSION PDE5 Inhibitors Sildenafil Co-administration with REYATAZ may A safe and effective dose in result in increased concentrations of the combination with REYATAZ has PDE5 inhibitor and an increase in PDE5- not been established for sildenafil inhibitor-associated adverse events. when used to treat pulmonary arterial hypertension. Sildenafil, The mechanism of interaction is CYP3A4 when used for the treatment of inhibition by atazanavir and/or ritonavir. pulmonary arterial hypertension, is contraindicated (see section 4.3). SEDATIVES Benzodiazepines Midazolam Midazolam and triazolam are extensively Co-administration of REYATAZ Triazolam metabolised by CYP3A4. Co- with triazolam or orally administration with REYATAZ may cause administered midazolam is a large increase in the concentration of contraindicated (see section 4.3), these benzodiazepines. No drug interaction whereas caution should be used study has been performed for the co- with co-administration of administration of REYATAZ with REYATAZ and parenteral benzodiazepines. Based on data for other midazolam. If REYATAZ is co- CYP3A4 inhibitors, plasma concentrations administered with parenteral of midazolam are expected to be midazolam, it should be done in an significantly higher when midazolam is intensive care unit (ICU) or similar given orally. Data from concomitant use of setting which ensures close clinical parenteral midazolam with other protease monitoring and appropriate medical inhibitors suggest a possible 3-4-fold management in case of respiratory increase in midazolam plasma levels. depression and/or prolonged sedation. Dosage adjustment for midazolam should be considered, especially if more than a single dose of midazolam is administered.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198) protease (HOS-085623) sildenafil (HOS-086162) ritonavir (HOS-084521) triazolam (HOS-086168) midazolam (HOS-086167)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage be486e27c0486d810d40c1b37da9b7f69c7a35ad1fcade19cc1e1d57a1b71724 · Zeichen 71400–75434 im Abschnitt

Wechselwirkungen · Reyataz

REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 60

HOS-112204 · Präparat HOS-093615

The mechanism of interaction is CYP3A4 and UGT1A1 inhibition. Concentrations of atazanavir (when given with ritonavir) were not significantly affected. Methadone, stable No significant effect on methadone No dosage adjustment is maintenance dose concentrations was observed. Given that necessary if methadone is co- (atazanavir 400 mg once daily) low dose ritonavir (100 mg twice daily) has administered with REYATAZ. been shown to have no significant effect on methadone concentrations, no interaction is expected if methadone is co-administered with REYATAZ, based on these data. PULMONARY ARTERIAL HYPERTENSION PDE5 Inhibitors Sildenafil Co-administration with REYATAZ may A safe and effective dose in result in increased concentrations of the combination with REYATAZ PDE5 inhibitor and an increase in PDE5- has not been established for inhibitor-associated adverse events. sildenafil when used to treat pulmonary arterial The mechanism of interaction is CYP3A4 hypertension. Sildenafil, when inhibition by atazanavir and/or ritonavir. used for the treatment of pulmonary arterial hypertension, is contraindicated (see section 4.3).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198) sildenafil (HOS-086162) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage b18d066e48bffe433295d60679cd4c3927cb2c9e30e4f13b4dcdeb50ae5a39f4 · Zeichen 74413–76443 im Abschnitt

Wechselwirkungen · Kivexa

Kivexa 600 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9

HOS-113481 · Präparat HOS-093937

Clinically significant interaction unlikely. Cimetidine eliminated only in part by renal organic cation transport system. CYTOTOXICS Cladribine/Lamivudine Interaction not studied. Therefore, the concomitant use of lamivudine with cladribine In vitro lamivudine inhibits the is not recommended (see intracellular phosphorylation of section 4.4). cladribine leading to a potential risk of cladribine loss of efficacy in case of combination in the clinical setting. Some clinical findings also support a possible interaction between lamivudine and cladribine OPIOIDS Methadone/Abacavir Abacavir: AUC  No Kivexa dosage adjustment (40 to 90 mg once daily for 14 Cmax 35% necessary. days/600 mg single dose, then 600 mg twice daily for 14 days) Methadone: CL/F 22% Methadone dosage adjustment unlikely in majority of Methadone/Lamivudine Interaction not studied. patients; occasionally methadone re-titration may be required.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198) cimetidine (HOS-085835) cladribine (HOS-085842)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-01-19T12:00:00Z · SHA-256 014b022d5230b58f7efa74f9573b1c2e42d28f6a3d171aa8848bc0f8c92c1380 · Passage 3bb42b8e96076847ca3aeb445cb6bf4f6cf7f1f0ef62e5fb0170f713aaf7d90c · Zeichen 6118–7873 im Abschnitt

Wechselwirkungen · Truvada

Truvada 200 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 23

HOS-113775 · Präparat HOS-093961

Tenofovir: AUC: ↑ 6% (↓ 1 to ↑ 13) Cmax: ↑13% (↑ 1 to ↑ 27) Cmin: NC NARCOTIC ANALGESICS Methadone/Tenofovir disoproxil Methadone: No dose adjustment of methadone AUC: ↑ 5% (↓ 2 to ↑ 13) is required. Cmax: ↑ 5% (↓ 3 to ↑ 14) Cmin: NC NC = not calculated. N/A = not applicable. 1 Data generated from simultaneous dosing with ledipasvir/sofosbuvir. Staggered administration (12 hours apart) provided

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) sofosbuvir (HOS-108928) methadone (HOS-086198) ledipasvir (HOS-110493)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-02-29T18:10:00Z · SHA-256 c649f98085684f03838a5e69a1a4e7a871850d61dfdc001f745e6b31db212087 · Passage 25f8a77f017229b7a064943b5d51b0bb8b1099be57b0f9f5c836e951de5c0d7a · Zeichen 43205–43901 im Abschnitt

Wechselwirkungen · Aptivus

Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 17–18

HOS-114836 · Präparat HOS-094169

17 Tadalafil 10 mg QD Tadalafil first-dose Cmax ↓ 22% It is recommended to prescribe Tadalafil first-dose AUC ↑ 133% tadalafil after at least 7 days of Aptivus with ritonavir dosing. CYP 3A4 inhibition and A safe and effective dose has not induction by tipranavir/r been established when used with Aptivus, co-administered with Tadalafil steady-state Cmax ↓ 30% low dose ritonavir. There is Tadalafil steady-state AUC ↔ increased potential for PDE5 inhibitor-associated adverse No clinically significant change events (which include visual is observed in tipranavir PK disturbances, hypotension, parameters. prolonged erection, and syncope). Narcotic analgesics Methadone 5 mg QD Methadone Cmax ↓ 55% Patients should be monitored for Methadone AUC ↓ 53% opiate withdrawal syndrome. Methadone Cmin ↓ 50% Dosage of methadone may need to be increased. R-methadone Cmax ↓ 46% R-methadone AUC ↓ 48%

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tadalafil (HOS-086316) methadone (HOS-086198) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 669a5b26c5bdcc545e77689dabe585e270a8da524ef0adb5485341efb0124443 · Zeichen 39606–41225 im Abschnitt

Wechselwirkungen · Aptivus

Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 18

HOS-114837 · Präparat HOS-094169

S-methadone Cmax ↓ 62% S-methadone AUC ↓ 63%

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 194cf065f42025f24ee882727edf29b7c7084bbfb6027af96ffb367fe7e2f033 · Zeichen 41252–41321 im Abschnitt

Wechselwirkungen · Suboxone

Suboxone 2 mg/0.5 mg sublingual tablets Suboxone 8 mg/2 mg sublingual tablets Suboxone 16 mg/4 mg sublingual tablets · Abschnitt 4.5 · PDF-Seite 8

HOS-115845 · Präparat HOS-094369

• Other central nervous system depressants, other opioid derivatives (e.g. methadone, analgesics and antitussives), certain antidepressants, sedative H1-receptor antagonists, barbiturates, anxiolytics other than benzodiazepines, neuroleptics, clonidine and related substances: these combinations increase central nervous system depression. The reduced level of alertness can make driving and using machines hazardous.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198) clonidine (HOS-088594)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-09-25T15:36:00Z · SHA-256 53df145bc12212064132de2f19d68d1c0074d2217b26658d050ac86495c25fa2 · Passage 24d2c8ef65ba0822e9fe6bd7f9f9f801588c02163cb7161e73937e01cb04be34 · Zeichen 1219–1664 im Abschnitt

Wechselwirkungen · Suboxone

Suboxone 2 mg/0.5 mg sublingual film Suboxone 4 mg/1 mg sublingual film Suboxone 8 mg/2 mg sublingual film Suboxone 12 mg/3 mg sublingual film · Abschnitt 4.5 · PDF-Seite 26

HOS-115874 · Präparat HOS-094369

• Other central nervous system depressants, other opioid derivatives (e.g. methadone, analgesics and antitussives), certain antidepressants, sedative H1-receptor antagonists, barbiturates, anxiolytics other than benzodiazepines, neuroleptics, clonidine and related substances: these combinations increase central nervous system depression. The reduced level of alertness can make driving and using machines hazardous.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198) clonidine (HOS-088594)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-09-25T15:36:00Z · SHA-256 53df145bc12212064132de2f19d68d1c0074d2217b26658d050ac86495c25fa2 · Passage 47156d08930c888aa24a077b7c8337b1c3f2b1cea07cc1f61575f8dfe4537eea · Zeichen 1226–1671 im Abschnitt

Wechselwirkungen · Prezista

PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 10

HOS-116324 · Präparat HOS-094447

A clinical study utilising a cocktail of medicinal products that are metabolised by cytochromes CYP2C9, CYP2C19 and CYP2D6 demonstrated an increase in CYP2C9 and CYP2C19 activity and inhibition of CYP2D6 activity in the presence of darunavir/ritonavir, which may be attributed to the presence of low dose ritonavir. Co-administration of darunavir and ritonavir with medicinal products which are primarily metabolised by CYP2D6 (such as flecainide, propafenone, metoprolol) may result in increased plasma concentrations of these medicinal products, which could increase or prolong their therapeutic effect and adverse reactions. Co-administration of darunavir and ritonavir with medicinal products primarily metabolised by CYP2C9 (such as warfarin) and CYP2C19 (such as methadone) may result in decreased systemic exposure to such medicinal products, which could decrease or shorten their therapeutic effect.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propafenone (HOS-084530) methadone (HOS-086198) flecainide (HOS-086203) ritonavir (HOS-084521) metoprolol (HOS-090094) warfarin (HOS-085950)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 1c69c1e904c5e45f21197cc74aaf3793a744795efd05ba12ed65d139c93b2ca1 · Zeichen 3809–4716 im Abschnitt

Wechselwirkungen · Prezista

PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 21–22

HOS-116415 · Präparat HOS-094447

21 Rosuvastatin rosuvastatin AUC ↑ 48%║ When administration of 10 mg once daily rosuvastatin Cmax ↑ 144%║ rosuvastatin and boosted ║ based on published data with PREZISTA is required, it is darunavir/ritonavir recommended to start with the lowest possible dose of rosuvastatin AUC ↑ 93%§ rosuvastatin and titrate up to the rosuvastatin Cmax ↑ 277%§ desired clinical effect while rosuvastatin Cmin ND§ monitoring for safety. § with darunavir/cobicistat 800/150 mg OTHER LIPID MODIFYING AGENTS Lomitapide Based on theoretical considerations Co-administration is boosted PREZISTA is expected to contraindicated (see section 4.3). increase the exposure of lomitapide when co-administered. (CYP3A inhibition) H2-RECEPTOR ANTAGONISTS Ranitidine # Boosted PREZISTA can be darunavir AUC ↔ 150 mg twice daily # darunavir Cmin ↔ co-administered with H2-receptor # darunavir Cmax ↔ antagonists without dose adjustments. IMMUNOSUPPRESSANTS Ciclosporin Not studied. Exposure to these Therapeutic drug monitoring of the Sirolimus immunosuppressants will be increased immunosuppressive agent must be Tacrolimus when co-administered with boosted done when co-administration PREZISTA. occurs. (CYP3A inhibition) Everolimus Concomitant use of everolimus and boosted PREZISTA is not recommended. INHALED BETA AGONISTS Salmeterol Not studied. Concomitant use of Concomitant use of salmeterol and salmeterol and boosted darunavir may boosted PREZISTA is not increase plasma concentrations of recommended. The combination salmeterol. may result in increased risk of cardiovascular adverse event with salmeterol, including QT prolongation, palpitations and sinus tachycardia. NARCOTIC ANALGESICS / TREATMENT OF OPIOID DEPENDENCE Methadone R(-) methadone AUC ↓ 16% No adjustment of methadone individual dose ranging R(-) methadone Cmin ↓ 15% dosage is required when initiating from 55 mg to 150 mg R(-) methadone Cmax ↓ 24% co-administration with boosted once daily PREZISTA. However, adjustment PREZISTA/cobicistat may, in contrast, of the methadone dose may be increase methadone plasma necessary when concomitantly concentrations (see cobicistat SmPC). administered for a longer period of time. Therefore, clinical monitoring is recommended, as maintenance therapy may need to be adjusted in some patients. Buprenorphine/naloxone buprenorphine AUC ↓ 11% The clinical relevance of the 8/2 mg–16/4 mg once buprenorphine Cmin ↔ increase in norbuprenorphine daily buprenorphine Cmax ↓ 8% pharmacokinetic parameters has norbuprenorphine AUC ↑ 46% not been established. Dose norbuprenorphine Cmin ↑ 71% adjustment for buprenorphine may norbuprenorphine Cmax ↑ 36% not be necessary when naloxone AUC ↔ co-administered with boosted PREZISTA but a careful clinical naloxone Cmin ND monitoring for signs of opiate naloxone Cmax ↔ toxicity is recommended.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198) lomitapide (HOS-086160) cobicistat (HOS-088111) rosuvastatin (HOS-086307) buprenorphine (HOS-086193) salmeterol (HOS-086285) tacrolimus (HOS-085202) ranitidine (HOS-085660) everolimus (HOS-086310) naloxone (HOS-109490) sirolimus (HOS-085172) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 5acbdf6c1f8cbcfa7417e6f43148a46845265b80041528b8854960cce50aae89 · Zeichen 63548–68815 im Abschnitt

Quellenpassagen (145)

Wechselwirkungen · Vfend

Wechselwirkungen · Vfend

Wechselwirkungen · Pegasys

Wechselwirkungen · Pegasys

Wechselwirkungen · Pegasys

Wechselwirkungen · Viread

Wechselwirkungen · Viread

Wechselwirkungen · Viread

Wechselwirkungen · Viread

Wechselwirkungen · Viread

Wechselwirkungen · Reyataz

Wechselwirkungen · Reyataz

Wechselwirkungen · Kivexa

Wechselwirkungen · Truvada

Wechselwirkungen · Aptivus

Wechselwirkungen · Aptivus

Wechselwirkungen · Suboxone

Wechselwirkungen · Suboxone

Wechselwirkungen · Prezista

Wechselwirkungen · Prezista